Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2020 from OUS - Photodynamic therapy (PDT)

6 publications found

Berge LAM, Andreassen BK, Stenehjem JS, Heir T, Furu K, Juzeniene A, Roscher I, Larsen IK, Green AC, Veierød MB, Robsahm TE (2020)
Use of Antidepressants and Risk of Cutaneous Melanoma: A Prospective Registry-Based Case-Control Study
Clin Epidemiol, 12, 193-202
DOI 10.2147/CLEP.S241249, PubMed 32110111

Grigalavicius M, Mastrangelopoulou M, Arous D, Juzeniene A, Ménard M, Skarpen E, Berg K, Theodossiou TA (2020)
Photodynamic Efficacy of Cercosporin in 3D Tumor Cell Cultures
Photochem Photobiol, 96 (3), 699-707
DOI 10.1111/php.13257, PubMed 32125700

Mastrangelopoulou M, Grigalavicius M, Raabe TH, Skarpen E, Juzenas P, Peng Q, Berg K, Theodossiou TA (2020)
Predictive biomarkers for 5-ALA-PDT can lead to personalized treatments and overcome tumor-specific resistances
Cancer Rep (Hoboken), e1278 (in press)
DOI 10.1002/cnr2.1278, PubMed 32737955

Napoli E, Stenberg VY, Juzeniene A, Hjellum GE, Bruland ØS, Larsen RH (2020)
Calibration of sodium iodide detectors and reentrant ionization chambers for 212Pb activity in different geometries by HPGe activity determined samples
Appl Radiat Isot, 166, 109362 (in press)
DOI 10.1016/j.apradiso.2020.109362, PubMed 32979756

Stenberg VY, Juzeniene A, Bruland ØS, Larsen RH (2020)
In situ Generated 212Pb-PSMA Ligand in a 224Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-positive Cells
Curr Radiopharm, 13 (2), 130-141
DOI 10.2174/1874471013666200511000532, PubMed 32389119

Stenberg VY, Juzeniene A, Chen Q, Yang X, Bruland ØS, Larsen RH (2020)
Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [212 Pb]Pb-NG001 for prostate cancer
J Labelled Comp Radiopharm, 63 (3), 129-143
DOI 10.1002/jlcr.3825, PubMed 31919866

 
Page visits: 442351